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Abstract To search for negative regulatory components of the
NF-UB activation pathways, we mutagenized Rat-1 ¢broblasts
and established a stable mutant cell line with a constitutive NF-
UB activity. This mutant cell line, designated as TK26, showed
permanently elevated I kappa B kinase (IKK) activity and a
genetically recessive phenotype revealed by somatic cell hybrid-
ization between TK26 and Rat-1. Our results suggested that
lack of a negative regulation of IKK could lead to permanent
NF-UB activation. The TK26 cell line will be useful to genet-
ically identify a component necessary for keeping the IKK com-
plex under an inactive form in resting cells.
+ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The nuclear factor-kappa B (NF-UB) family of transcription
factors controls the expression of various genes involved in
in£ammatory and immune responses [1^4]. Under physiolog-
ical conditions, NF-UB is sequestered in the cytoplasm by the
inhibitor of I kappa B (IUB) proteins. Exposure of cells to a
variety of extracellular stimuli leads to rapid phosphorylation,
ubiquitination and proteolytic degradation of IUB, which free
NF-UB to translocate to the nucleus, where it regulates gene
transcription [5^8]. The multisubunit I kappa B kinase (IKK)
complex lies at a converging regulatory step leading to IUB
phosphorylation. The core of the IKK complex consists of
two catalytic subunits, IKK1/K and IKK2/L and a non-cata-
lytic regulatory subunit, NF-UB essential modulator (NEMO/
IKKQ) [9^15]. Activation of IKKs is supposed to depend on
phosphorylation of two serine residues in their activation loop
and kinases responsible for this phosphorylation are under
intense investigation. NF-UB is known to be critically involved
in a variety of pathological conditions characterized by its
aberrant activation [16] or caused by its defective signaling
[17]. Thus, it has become increasingly important to elucidate
the molecular mechanisms of NF-UB dysregulation. It should
be noted that many of the disease states are characterized by
dysregulation of the IKK activity, resulting in permanent or
defective NF-UB activity [18]. This may re£ect a central role
that the IKK complex plays in the NF-UB signaling pathways.
Normally, the IKK complex should be kept quiescent without
stimulation, and following its activation, should be down-
regulated at an appropriate time point. The mechanisms of
inducible IKK activation in response to a wide variety of
stimuli through cell surface receptors have been studied exten-
sively, but little is known as to constitutive IKK activation or
negative regulation of the IKK complex [19].
Given that a number of cellular regulatory systems such as
the mitogen-activated protein kinase cascades, cell cycle reg-
ulation or apoptosis require both positive and negative regu-
lators, it is reasonable to assume that the NF-UB signaling is
also regulated negatively at multiple steps, loss of which may
lead to its permanent activation. However, negative regulators
are more di⁄cult to identify in general unless they are inacti-
vated by certain viral proteins [20]. One successful approach
to this issue would be forward genetics, which has resulted in
many gene discoveries based on their function [21]. To gain
new insight into negative regulation of NF-UB, we mutagen-
ized a rat ¢broblastic cell line, Rat-1, which otherwise exhibits
a very low NF-UB activity and is known to be able to grow
under a high NF-UB activity, and report here a genetically
recessive mutant cell line with a constitutive IKK activity.
2. Materials and methods
2.1. Reagents
Hygromycin B and cycloheximide were purchased from Wako.
Blasticidin S was purchased from ICN. Lipopolysaccharide (LPS),
poly d (I-C), neomycin (G418), puromycin and ganciclovir were pur-
chased from Sigma.
2.2. Recombinant plasmids
Plasmids IgU2bsrH, IgU-ConA luciferase and EF1-lacZ were de-
scribed previously [13,22]. Plasmid IgU2tkH was constructed by re-
placing the bsr gene of IgU2bsrH with the Herpes Simplex virus thy-
midine kinase (HSV-TK) gene, so that this gene can be expressed
under the NF-UB-dependent promoter. Plasmid pPUR was purchased
from Clontech. A dominant negative form of NEMO (aa 97^412) was
described previously [23].
2.3. Antisera
Anti-p50, anti-RelA, anti-RelB and anti-IUBL sera were kind gifts
from Dr. Alain Israe«l (Institute Pasteur, Paris, France). Anti-IUBK,
anti-p52, anti-cRel and anti-actin antibodies were purchased from
Santa Cruz. Anti-IKK1 antibody was purchased from Imgenex.
Anti-NEMO rabbit polyclonal antiserum (serum 44106) was described
previously [24].
2.4. Cell culture, DNA transfection and mutagenesis
All cells were grown in DMEM (Dulbecco’s modi¢ed Eagle’s me-
dium) supplemented with 10% fetal calf serum and antibiotics. To
establish Rat-1 ¢broblasts conditionally resistant to blasticidin S,
Rat-1 cells were transfected with pIgU2bsrH by the calcium phosphate
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coprecipitate method. Stable transfectants were selected with 500 Wg/
ml of hygromycin B. Individual hygromycin-resistant clones were iso-
lated and tested for their ability to survive a high dose of blasticidin S
selection after hybridization by polyethylene glycol with 5R cells that
express the Tax protein of human T cell lymphotropic virus type I and
lack NEMO. One of the established clones named B5 was used for
further studies.
To generate mutant cells, approximately 40 million B5 cells were
subjected to four rounds of chemical mutagenesis with 10 Wg/ml of
ICR191 (Sigma), which killed about 80^90% of cells in each round of
mutagenesis. After the last round of mutagenesis, cells were subjected
to selection with 3 Wg/ml of blasticidin S. After 2 to 3 weeks of
selection, individual colonies were ring-cloned and expanded. A blas-
ticidin S-resistant clone 2-7 was transfected with the pIgU2tkH and
pPUR plasmids and selected with 2 Wg/ml of puromycin. One isolated
clone TK26, which exhibited the phenotype indistinguishable from
that of 2-7 cells, was chosen for further experiments. TK26 cells
were hybridized with Rat-1 cells resistant to neomycin (G418) and
selected in media containing 500 Wg/ml of G418 and 2 Wg/ml of puro-
mycin for 7^10 days before pooled hybrid cells were examined for
NF-UB-DNA binding and IKK activity.
For measurement of luciferase activity in transiently transfected
cells, approximately 1.5U105 cells were plated in 6-well plates. The
next day, cells were co-transfected with 0.25 Wg of IgU-luciferase re-
porter plasmid, 0.25 Wg of EF1-lacZ plasmid, and 2 Wg of either vector
or e¡ector plasmid using the calcium phosphate coprecipitate method.
Cells were harvested 48 h after transfection and assayed for luciferase
activity. Luciferase values were normalized based on L-galactosidase
activity. Experiments were repeated three times in duplicate.
2.5. Preparation of cell extracts
Cells were washed twice with cold phosphate-bu¡ered saline and
resuspended in hypotonic bu¡er (20 mM HEPES (pH 7.8), 10 mM
KCl, 0.15 mM EGTA, 0.15 mM EDTA), supplemented with protease
inhibitors (0.1 mM PMSF, 1 Wg/ml leupeptin and 1 Wg/ml aprotinin).
After 15 min of incubation at 4‡C, NP40 was added to 1% and the
cells were vortexed for 20 s. After centrifugation, supernatants were
recovered and used as cytoplasmic fraction. Nuclear pellets were
brie£y washed with isotonic bu¡er (20 mM HEPES (pH 7.8), 100
mM NaCl, 0.1 mM EDTA and 25% glycerol) and resuspended in
extraction bu¡er (20 mM HEPES (pH 7.8), 400 mM NaCl, 0.1 mM
EDTA and 25% glycerol, 1 mM DTT, 0.1 mM PMSF). After 30 min
of incubation at 4‡C with occasional agitation, supernatants were
recovered by centrifugation at 14 000 rpm for 2 min and stored at
380‡C until use as nuclear extracts. Whole cell lysate was prepared by
lysis of cells with RIPA bu¡er (20 mM Tris^HCl (pH. 8.0), 137 mM
NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, 1% NP40, 0.5%
deoxycholate, 0.1% SDS and 0.1 mM PMSF). Protein concentrations
of cytoplasmic fraction, nuclear fraction and whole cell lysate were
determined by the Bradford method.
2.6. Electrophoretic mobility shift assays (EMSAs)
Five micrograms of nuclear extracts were added to binding bu¡er
for NF-UB probe (10 mM HEPES (pH 7.8), 100 mM NaCl, 1 mM
EDTA, 25% glycerol ¢nal), or to binding bu¡er for activator protein-
1 (AP-1) probe (12 mM HEPES (pH 7.2), 60 mM KCl, 0.6 mM
EDTA, 0.6 mM DTT), 1 Wg poly d (I-C) and Q-32P-labeled UB probe
derived from the H-2Kb promoter [25], or Q-32P-labeled AP-1 probe
(5P-GATCGTGATGACTCAGGTT-3P) and incubated for 30 min at
room temperature. Samples were run on a 5% polyacrylamide gel in
0.5UTris^borate EDTA (TBE). For competition studies, excess unla-
beled probe was included in the binding reaction.
2.7. Western blot analysis
Proteins in cytoplasmic extracts were fractionated on 8 or 10%
SDS^polyacrylamide gels, transferred onto immobilized membranes
(Millipore), and blots were revealed with an enhanced chemilumines-
cence detection system (NEN1 Life Science products). When neces-
sary, membranes were stripped by incubation in stripping bu¡er (62.5
mM Tris^HCl (pH. 6.8), 100 mM 2-mercaptoethanol, 2% SDS) for 30
min at 50‡C with constant agitation, washed and then reprobed with
other antibodies as indicated.
2.8. Immunoprecipitation and kinase assay
Approximately 4U106 cells were washed twice with cold phosphate-
bu¡ered saline and resuspended in hypotonic bu¡er (20 mM HEPES
(pH7.8), 10 mM KCl, 0.15 mM EGTA, 0.15 mM EDTA), supple-
mented with phosphatase inhibitors (0.1 mM PMSF, 1 Wg/ml leupep-
tin, 1 Wg/ml aprotinin, 100 WM Na3VO4 and 20 mM L-glycerophos-
phate). After 15 min of incubation at 4‡C, NP40 was added to 1% and
the cells were vortexed for 20 s. The supernatants (400 Wg) were sub-
jected to immunoprecipitation with NEMO antiserum (anti-NEMO)
in TNT bu¡er (20 mM Tris^HCl (pH 7.5), 200 mM NaCl and 1%
Triton X-100). Immunoprecipitates were collected on protein G-Seph-
arose beads, which were washed three times with TNT bu¡er and then
divided into two, 50% for detection of IKK1 in the immunoprecipi-
tates and 50% for in vitro kinase assay. Samples for kinase assay were
washed three times with kinase reaction bu¡er (20 mM HEPES (pH
7.5), 10 mM MgCl2, 50 mM NaCl). Kinase reaction was conducted in
the kinase reaction bu¡er supplemented with 100 WM Na3VO4, 20
mM L-glycerophosphate, 2 mM DTT and 20 WM ATP at 30‡C for
30 min in the presence of 5 WCi of (Q?-32P)-ATP and GST-IUBK (1-72)
wild type or GST-IUBK (1-72) S32A/S36A mutant protein as sub-
strates [13]. Phosphorylated proteins were resolved on 12% SDS^poly-
Fig. 1. Isolation of a mutant cell line, TK26.
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Fig. 2. Elevated NF-UB DNA binding and IKK activity in a mutant cell line, TK26. A: Five micrograms of nuclear extracts prepared from B5
(lane 1, 4 and 6), B5 stimulated with LPS for 1 h (lane 2) and TK26 (lane 3, 5 and 7) were analyzed by EMSAs, using the NF-UB-binding se-
quence derived from the H-2 Kb promoter and AP-1-binding sequence as probes. For competition studies, 50-fold excess of unlabeled probe
was included in the binding reaction. B: The protein composition was determined by pre-incubating 5 Wg of nuclear extracts with antibodies
speci¢cally directed against p50, RelA, RelB, p52 or cRel for 30 min at room temperature. C: Cytoplasmic extracts (400 Wg) were immunopre-
cipitated with anti-NEMO and speci¢c IUB kinase activity was determined by in vitro immune complex kinase assay, using GST-IUBK (1-72)
wild type or GST-IUBK (1-72) S32A/S36A mutant proteins as substrates. To control for amounts of input and immunoprecipitated IKK1, part
of the immunoprecipitates or cell extracts used for the kinase assay was subjected to Western blot analysis.
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Fig. 3. Distinct IKK and IUB kinetics in TK26 and Rat-1 cells expressing Tax. A: Approximately 50 Wg of cytoplasmic extracts were subjected
to Western blot analysis with IUBK or IUBL antisera. The same blot was then probed with anti-actin serum, showing equivalent sample loading
in each lane. B: Approximately 50 Wg of whole cell lysates were subjected to Western blot analysis with a p52-antibody. The positions for p100
and p52 are indicated by the arrows. The same blot was then probed with anti-actin serum. C: Cytoplasmic extracts (400 Wg) from TK26 and
M319-5 untreated or treated with 25 Wg/ml of cycloheximide for 1 or 2 h were subjected to immunoprecipitation with anti-NEMO, and speci¢c
IUBK kinase activity was determined by in vitro immune complex kinase assay with GST-IUBK (1-72) wild type as substrates. Western blotting
was performed to control for amounts of IKK1 in each cell lysate or immune complexes. D: Tk26 and Tax-expressing M319-5 cells were
treated with 25 Wg/ml of cycloheximide for the indicated periods, and the steady-state levels of IUBK were determined by Western blot analysis.
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acrylamide gels and revealed by autoradiography. Amounts of IKK1
in each lysate or immunoprecipitates were veri¢ed by Western blot
analysis.
3. Results
3.1. Generation of a mutant cell line
We attempted to generate a mutant cell line with a consti-
tutive NF-UB activity through chemical mutagenesis of Rat-1
¢broblasts, aiming at identi¢cation of a negative regulator of
the NF-UB signaling. Rat-1 cells had been used successfully
for genetic studies in the NF-UB signaling pathway [13]. We
¢rst established sublines of Rat-1 cells capable of expressing
an inducible drug resistance gene under elevated NF-UB ac-
tivity (Fig. 1). A conditional drug resistance gene, IgU2bsrH,
contains the blasticidin deaminase gene [22] linked to a min-
imal IL-2 promoter following three repeats of the NF-UB-
binding element derived from the immunoglobulin U gene.
Rat-1 cell clones obtained by stable transfection with this
construct were tested for survival in the presence of blasticidin
S following hybridization with 5R cells, which express the Tax
protein of human T cell leukemia virus type 1 but lack
NEMO [13]. Hybrid cells express Tax that persistently acti-
vates NF-UB, and should eventually survive the drug selec-
tion. One of the transfected Rat-1 cell clones, B5, was chosen
for further experiments, as hybrids between B5 and 5R cells
were able to survive selection with a high dose of blasticidin S
and showed elevated NF-UB DNA-binding activity (data not
shown). There could be seen no survival of B5 cells cultured in
the presence of a low concentration of the drug without the
hybridization step, demonstrating that B5 is amenable to mu-
tagenesis and the following lethal selection. B5 cells were then
subjected to four rounds of mutagenesis with a frameshift
mutagen ICR191 followed by selection in medium containing
blasticidin S. Of 27 cell clones that survived blasticidin S
selection, we found one clone, 2-7, that stably showed an
elevated NF-UB DNA-binding activity in EMSAs. Subse-
quently, sublines of 2-7 cells were established which could
express the thymidine kinase gene derived from Herpes Sim-
plex virus (HSV-TK) under the control of the same NF-UB-
dependent promoter as that for the blasticidin deaminase
gene. Since HSV-TK is known to kill cells e⁄ciently in the
presence of ganciclovir, 2-7 cells carrying this HSV-TK con-
struct were supposed to be killed in the presence of ganciclovir
because of their high NF-UB activity, but to be able to survive
if they restore the normal NF-UB activity. TK26 cells showed
strong NF-UB DNA-binding activity similar to that of 2-7
cells, but no signi¢cant change in the AP-1 DNA-binding
activity, when compared to B5 cells. (Fig. 2A).
3.2. Characterization of TK26 cells
To determine the composition of the NF-UB complexes
bound to an NF-UB-speci¢c DNA probe in EMSAs, we per-
formed supershift analysis, using anti-p50, anti-RelA or anti-
RelB antibodies. Anti-p50 and anti-RelA antibodies readily
supershifted the two protein^DNA complexes that appeared
following stimulation of B5 cells with LPS (Fig. 2B, lanes 2, 3
and 4), indicating that the faster migrating complexes but not
RelA contain p50, and that the more slowly migrating com-
plexes contain p50 and RelA. Regarding TK26, the faster
migrating complexes contain p50, but not RelA, and the
more slowly migrating complexes were supershifted by anti-
p50 antibody to an extent similar to B5 cells. The anti-RelA
antibody failed to supershift e⁄ciently the slowly migrating
complexes, but instead, anti-RelB antibody supershifted the
faster migrating complexes and attenuated the binding as a
whole. Neither anti-p52 nor anti-cRel a¡ected the binding.
We next asked if the enhanced nuclear DNA-binding activ-
ity in TK26 cells resulted from constitutive IKK activation. In
vitro kinase assays using anti-NEMO (NF-UB essential mod-
ulator) antibody detected a markedly elevated phosphorylat-
ing activity on recombinant IUBK substrates in immunopreci-
pitates from TK26 cells (Fig. 2C). This activity failed to
phosphorylate a mutant form of the substrate with amino
acid substitutions of alanine for serine at the residues 32
and 36 of IUBK, establishing the speci¢city of the activity.
In each assay, equivalent amounts of the IKK1 protein were
detected in the immune precipitates by Western blot analysis.
Thus, IKK is constitutively activated in TK26 cells. Western
blot studies revealed that the steady-state levels of IUBK and
IUBL in TK26 are similar to those in the parental cells (Fig.
3A), while NF-UB2/p52 is aberrantly expressed in TK26 (Fig.
3B), which was even more abundant than that in Rat-1 cells
expressing Tax, suggesting active processing of its precursor
p100 in TK26 cells. We also demonstrate a rapid down-regu-
lation of the IKK activity in TK26 cells when treated with
cycloheximide, a protein synthesis inhibitor, which contrasts
with the sustained IKK activity in M319-5 cells expressing
Tax (Fig. 3C) [13]. Consistently, the steady-state level of
IUBK in TK26 cells was barely a¡ected following protein syn-
thesis inhibition, whereas this protein disappeared quickly in
Tax-expressing cells (Fig. 3D). Moreover, a dominant negative
form of NEMO, known to suppress TNFK-mediated NF-UB
activation, potently counteracted Tax-mediated NF-UB activa-
tion, while its e¡ects were only marginal in TK26 cells (Fig. 4).
These results suggested distinct mechanisms of persistent IKK
activation in TK26 and Tax-expressing cells.
We next examined if TK26 can respond to LPS and further
activate NF-UB. As shown in Fig. 5A, both IUBK and IUBL
proteins disappeared shortly after LPS treatment in B5 cells,
Fig. 4. A dominant negative form of NEMO fails to suppress
NF-UB activity in TK26 cells. TK26 and M319-5 cells were transi-
ently transfected with 0.25 Wg of IgU-ConA luciferase and EF1-lacZ
along with 2 Wg of e¡ector plasmids, pcDNA3HA control vector or
indicated amounts of expression vector for a dominant negative
form of NEMO (dN97 NEMO). The total amount of the e¡ector
plasmids was adjusted to 2 Wg. Results are shown as average lucifer-
ase values relative to that of vector-transfected cells obtained by
three independent experiments in duplicate.
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while the steady-state levels of these proteins did not signi¢-
cantly change in TK26 cells. Fig. 5B shows only a marginal
elevation of DNA-binding activity in TK26 cells treated with
LPS, which contrasts to a sharp induction and subsequent
down-regulation of the DNA-binding activity in B5 cells.
We next examined the kinetics of IKK activation in LPS-
stimulated B5 and TK26 cells (Fig. 5C). In B5 cells, IKK
activity associated with NEMO rapidly increased and then
quickly decreased following LPS treatment. TK26 cells
showed a similar increase in IKK activity additive to its ba-
sally elevated one. Thus LPS treatment of TK26 cells further
activated IKK, but did not result in the disappearance of the
IUB proteins, so that the ultimate nuclear NF-UB-DNA-bind-
ing activity was not signi¢cantly altered.
3.3. The mutation in TK26 is recessive
We further analyzed the genetic phenotype of the mutation
by somatic cell hybridization. The phenotype of hybrid cells
between the mutant and wild type cells should provide an
answer to the question as to whether TK26 cells carry a
gain of function (dominant) mutation or loss of function (re-
cessive) mutation. For this purpose, parental Rat-1 cells were
fused to TK26 and stable hybrids were established. The ob-
tained hybrids restored the DNA binding and IKK activity as
low as those of B5 cells (Fig. 6A,B). This indicates that TK26
cells carry a recessive mutation that can be complemented by
cell fusion with wild type cells.
4. Discussion
We hypothesized that NF-UB might become permanently
activated without its negative regulation. To test this hypoth-
esis and identify a component necessary for keeping NF-UB in
a resting state, we tried to alter gene expression through
chemical mutagenesis and generated a stable mutant cell line
with a constitutive NF-UB activity. Both IUBK and IUBL were
shown to be present in TK26, therefore the elevated NF-UB
activity could not be ascribed to a lack of these inhibitors.
Fig. 5. Response of TK26 to LPS. A: Approximately 50 Wg of cytoplasmic extracts was subjected to Western blot analysis with IUBK or IUBL
antisera. B: Five micrograms of nuclear extracts prepared from B5 and TK26 cells stimulated with 15 Wg/ml of LPS for the indicated time
were analyzed by EMSAs, using the NF-UB-speci¢c probe. C: Cytoplasmic extracts prepared from the cells used for EMSAs were subjected to
immunoprecipitation with anti-NEMO and IKK activity was determined by in vitro immune complex kinase assay with GST-IUBK (1-72) as a
substrate.
FEBS 26738 7-11-02
N. Chinanonwait et al./FEBS Letters 531 (2002) 553^560558
The constitutive NF-UB activity resulted most likely from the
elevated IKK activity revealed by the in vitro kinase assay
following immunoprecipitation with NEMO, although we
were unable to determine whether the elevated IKK activity
in TK26 was caused by a lack of suppressor at the level of the
IKK complex or by a deregulated upstream signaling mole-
cule. However, IKK activation through an autocrine stimula-
tion of cell surface receptor seemed unlikely, because exposure
of Rat-1 cells to the supernatant of TK26 cells did not result
in any NF-UB activation (data not shown). Interestingly, the
supershift assays revealed that NF-UB complexes present in
the nucleus of TK26 include substantial amounts of p50 and
RelB as well as a tiny amount of RelA. This contrasts with
the nuclear NF-UB complexes detected in Rat-1 cells either
stimulated with LPS or stably expressing Tax, which are com-
prised of p50 and RelA [26]. The distinct nuclear NF-UB
components may result from a qualitative di¡erence in the
active IKK complex. RelB di¡ers in its regulation from the
other two NF-UB activators, RelA and cRel, that are con-
trolled by IUB proteins [27,28]. Previous studies revealed
that p100 is associated with RelB and inhibits its nuclear
localization, but IUBK, IUBL, IUBO or p105 are not [29]. In-
deed, nuclear translocation of RelB in TK26 cells is associated
with aberrant expression of p52, which could result from en-
hanced p100 processing induced by constitutive IKK activity.
P100 has a potent IUB function and its expression is induced
by NF-UB activation. It is also known that processing of p100
is not triggered by the classical NF-UB activation that requires
NEMO and IKK2 [30]. Thus, constitutive NF-UB activation
may be achieved if the powerful IUB function of p100 is dis-
rupted. LPS stimulation requires NEMO for IKK activation
and causes rapid up-regulation and subsequent down-regula-
Fig. 6. Genetically recessive phenotype of TK26 cells. A: EMSAs of B5, TK26 and a pool of hybrid cells between TK26 and Rat-1. Five
micrograms of nuclear extracts were analyzed using the H-2 Kb-derived UB probe. B: In vitro kinase assay was conducted, using cytoplasmic
extracts derived from the indicated cell lines. Western blotting was performed to control for amounts of IKK1 as described in Fig. 2C.
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tion of the IKK activity within 4 h. The poor increase in the
DNA-binding activity of TK26 cells in response to LPS de-
spite the additive IKK activation may be explained by a pos-
sible rapid turnover of IUB proteins owing to the elevated
IKK activity. The actual turnover of IUB proteins in TK26
cells is, however, unable to be evaluated in the presence of
cycloheximide because the IKK activity in this cell line is
sensitive to protein synthesis inhibition as is shown in Fig.
3C. This point remains to be addressed by a pulse chase
analysis. It was recently reported that persistent NF-UB acti-
vation by Tax involved chronic phosphorylation of IKK2 and
NEMO [31]. Indeed, a dominant negative form of NEMO
e⁄ciently inhibited Tax-mediated NF-UB activation while it
suppressed the reporter gene activation only marginally in
TK26 cells. Moreover, treatment of TK26 cells with cyclo-
heximide rapidly abolished the IKK activity, whereas it barely
a¡ected LPS- (data not shown) or Tax-mediated IKK activa-
tion in Rat-1 cells, indicating that a labile factor mediates the
permanent IKK activation in TK26 cells and that this IKK
activation depends on a mechanism distinct from those for
Tax or LPS. This particular feature of chronic IKK activation
is also seen in cells established from patients with certain
disease conditions (Miura and Yamaoka, unpublished obser-
vation), thus making it important to elucidate the mechanism
of IKK activation in TK26 cells.
Finally, the cell hybridization experiment indicated that
TK26 cells carried a genetically recessive phenotype and hence
were amenable to genetic complementation. Attempts at ret-
roviral expression cloning are now underway to identify a
gene product that is responsible for the constitutive IKK ac-
tivation in TK26. Inhibition of aberrant NF-UB activity has
received much attention to control certain malignancies, neu-
rodegenerative and in£ammatory diseases. Down-regulation
of NF-UB activity can be achieved by expression of the
IUBK protein or by a variety of natural and designed mole-
cules, including antioxidants, protease inhibitors, salicylate,
arsenite, proteasome inhibitors and peptides. [32]. Most of
these reagents target molecules that work for activation at
the level or downstream of the IKK complex, thereby inhibit-
ing the general NF-UB activation pathway. A better under-
standing of the mechanisms of NF-UB activation in each
pathological condition should result in the development of
reagents that can speci¢cally inhibit abnormal signalings and
eventually contribute to establishing a new therapeutic strat-
egy.
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